LYCOS RETRIEVER 
Tamiflu: Patients
built 635 days ago
FDA employees looked at 596 cases - most of them in Japan - of patients experiencing psychiatric side-effects which may be linked to Tamiflu use. Three Japanese adults committed suicide while on Tamiflu while five children died. Since 1999, when Relenza was approved, there have been 115 reports of psychiatric events, of which 74 were children.
Source:
Hurley says there is no evidence Tamiflu caused the episodes and notes that similar symptoms have been reported in flu patients who had not taken Tamiflu. He says clinical studies have found no increased risk for psychiatric or neurologic disturbances, and the company's evaluation of scientific data found no "potential mechanisms for Tamiflu to cause (central nervous system) effects." He says the company is doing further studies.
Source:
It is recommended that the patient should not miss any of his Tamiflu doses. If a dose is missed, it should be taken as soon as possible, provided that it is not about time for the next Tamiflu dose. You must not take a double dose of Tamiflu, or two doses of the drug separated by less than 2 hours from one another.
Source:
FDA staffers are recommending a stronger label warning for Tamiflu to note patient deaths and suggest close monitoring children for behavioral changes. For Relenza, addition of a warning about hallucinations and delirium is recommended.
Source:
Nearly 600 cases of psychiatric problems have been reported in Tamiflu patients, with 75 percent of them coming from Japan. Five children there have died after "falling from windows or balconies or running into traffic," according to the FDA.
Source:
FDA approved Tamiflu (oseltamivir phosphate), an oral anti-viral drug for the treatment of uncomplicated influenza in patients one year and older whose flu symptoms have not lasted more than two days. This product is approved to treat Type A and B influenza; ... the majority of patients included in the studies were infected with type A, the most common in the U.S. Efficacy of Tamiflu in the treatment of influenza in subjects with chronic cardiac disease and/or respiratory disease has not been established.
Source:
MORE ABOUT
Patients